News

HealthFactors and Koronis Biomedical Technologies are partnering on developing equipment to help people with respiratory conditions associated with chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The collaboration is aimed at creating smart inhaler devices that are so effective and easy to use that they become part of mainstream…

Duke University and Boehringer Ingelheim Pharmaceuticals will collaborate on a different kind of chronic obstructive pulmonary disease study over the next five years. Instead of obtaining information from medical records and tests, researchers will obtain it from talking with each of the 850 patients in the study every six months. The goal…

Ventec Life Systems announced that the U.S. Food and Drug Administration (FDA) has given 510(k) clearance to the company’s VOCSN life support device, which combines five respiratory therapies into one portable unit. VOCSN incorporates a critical care ventilator, a 6 l/min portable oxygen concentrator, a touch-button cough assist, a hospital-grade suction system, and…

U.S. pharmacies have begun carrying the Utibron Neohaler treatment-dispensing device as a long-term maintenance treatment for airflow obstruction in chronic obstructive pulmonary disease (COPD), Sunovion Pharmaceuticals announced. The powder that the device dispenses, which is a combination of  indacaterol and glycopyrrolate, is aimed at preventing bronchospasms in people with COPD.

Stem cell therapy reduced lung inflammation and improved lung damage repair in a mouse model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The findings were presented at the Lung Science Conference recently in Estoril, Portugal. Mesenchymal stem cell (MSC) therapy uses stem cells (multipotent cells that can differentiate into a variety…

Hospital readmissions for chronic obstructive pulmonary disease (COPD) are linked to readmissions for other conditions as well as patients’ own experiences while hospitalized, such as communication with nurses, staff responsiveness, pain management and discharge information. The study reporting the findings is titled “Chronic Obstructive Pulmonary Disease Readmissions and…

The COPD Foundation has established the JW Walsh Fund to Cure COPD in honor of its late founder and director emeritus John W. Walsh, who died on March 7 this year at the age of 68. The memorial fund was created as a way to honor Walsh’s commitment to…

Pulmatrix was granted an important patent from the European Union (EU) for its proprietary iSPERSE technology, a platform for inhaled drug delivery based on unique properties developed for the treatment of lung diseases such as chronic obstructive pulmonary disease (COPD). “This new patent shows our continued ability to obtain patents that protect…

AstraZeneca and Circassia are partnering to develop and commercialize two inhaled respiratory treatments for chronic obstructive pulmonary disease (COPD) in the United States, Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide). Tudorza was approved by the U.S. Food and Drug Administration (FDA) in 2012, and its marketing began that…